OnCo
ideasIdea

Launch prices indexed to the ESMO benefit scale, revisited when survival matures

Pay more for drugs that clearly help people live longer or better, and less for those that barely move the needle, using a public benefit scale doctors already use.

National payers adopt a rule that reimbursed price at launch is tied to the ESMO Magnitude of Clinical Benefit Scale (or ASCO Value Framework) grade of the pivotal evidence, with a mandatory renegotiation when overall survival or quality-of-life data mature. Grade 4 to 5 (or A to B in curative settings) commands a premium band; grade 1 to 2 is reimbursed only at or near the price of the comparator. Several European payers already consult the scale informally; making the link explicit and automatic changes the return calculus for marginal drugs before they enter development.

Hypothesis
Explicit MCBS-indexed pricing across a group of countries lowers the average launch price of low-benefit oncology drugs by at least 30% and, within eight years, increases the proportion of pivotal trials designed to achieve high MCBS grades (overall survival, quality of life endpoints).
Rationale
Value-based frameworks exist and are validated but have no teeth; where price is linked to benefit (Germany's AMNOG added-benefit assessment, France's ASMR rating) evidence of a shift in development priorities has been reported. Oncology has the best-developed benefit scales of any specialty.
What would test it
A payer coalition applies the rule to all new oncology reimbursements for three years and compares launch prices and pivotal trial designs of subsequent filings with a control set of countries.
Maturity
speculative
Who has to act
payer
Cost to try
Small (under $1M)
Years to first evidence
3
Bottlenecks it attacks
  • Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
  • Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.

Connected

8top

Pages like this

not linked directly; found by shared links

institutions

2
American Society of Clinical Oncology (ASCO)European Society for Medical Oncology (ESMO)

terms

2
Overall survival (OS)Progression-free survival (PFS)

ideas

2
Outcome-based annuity payments for potentially curative one-time therapiesPatent term extension scaled to proven survival gain

bottlenecks

2
Incentives reward me-too drugs and marginal gainsPrices and value